| |
property for sale in balchik varna brovets bansko bulgaria
News and Information Article
Michael F. Bigham and Daniel R. Omstead, Eng.ScD, Join Board of Directors
CHELMSFORD, Mass., Nov. 28 // -- Magellan Biosciences, an
emerging leader in clinical-diagnostic markets worldwide, announced today
that it has closed a new $50 million round of debt and equity financing,
led by new investor, Abingworth Management. Other first-time investors
include Hambrecht & Quist Capital Management, and KBL Healthcare Ventures.
Magellans primary equity sponsor, Ampersand Ventures, as well as other
existing investors, New England Partners Capital LP, Nexus Medical Partners
II SICAR, and Boston Community Venture Fund, also participated. Michael F.
Bigham, an Abingworth director responsible for the companys Boston office,
and Daniel R. Omstead, president and CEO of Hambrecht & Quist Capital
Management (HQCM), joined Magellans board.
"Abingworth and Hambrecht & Quist Capital Management are marquis names
in life-sciences investing, and their support, along with that of the other
investors, follows the enormously successful launch of our point-of-care
CLIA-waived LeadCare II blood-lead-testing system," said Magellan President
and Chief Executive Officer, Robert J. Rosenthal, PhD. "This new funding
will allow us to expand our growth through further new product development
as well as strategic acquisitions. We plan to expand our presence in
products for clinical-diagnostics, hospital-based labs, and near-patient
testing that improve health outcomes."
Dr. Rosenthal continued, "Were very pleased to have Michael Bigham and
Dan Omstead join our board. They each bring with them a wealth of
experience in the life-sciences/biotech arenas, and we look forward to
their insights as we continue to build Magellan into a world-class
company."
Mr. Bigham, who joined Abingworth in 2002, has 20 years of experience
serving life-sciences companies in operational and investment-banking
roles. He was president and chief executive of Coulter Pharmaceuticals from
July 1996 until it merged into Corixa in December 2000, when he became
Corixas vice chairman. Previously, he was an early employee at Gilead
Sciences where he spent eight years serving in various capacities,
including executive vice president of operations and CFO. Before joining
Gilead, Mr. Bigham was a partner at Hambrecht & Quist, where he became
co-head of healthcare investment banking. A certified public accountant, he
has a bachelors degree in commerce from the University of Virginia and a
masters in business from Stanford University.
Dr. Omstead has been president of HQCM since 2001. He also serves as
president of H&Q Life Sciences Investors and H&Q Healthcare Investors, two
NYSE listed closed-end mutual funds that make venture and public equity
investments principally in small, emerging healthcare-related companies.
Prior to joining HQCM, Dr. Omstead was president and CEO of Reprogenesis,
Inc., a private biotech company developing therapies in the field of
regenerative medicine. In 2000, Reprogenesis was merged with two other
biotech companies to form Curis, Inc. Previously, Dr. Omstead was senior
vice president, research and development at Cytotherapeutics, Inc., a
public biotech company that developed central nervous system therapies.
Prior to entering the biotech industry, he worked for 14 years in the
pharmaceutical industry. Dr. Omstead holds doctoral and masters degrees in
chemical engineering and applied chemistry from Columbia University and a
bachelors degree in civil engineering from Lehigh University.
About Magellan Biosciences
Magellan serves the worldwide clinical-diagnostics market with rapid
point-of-care analyzers and automated systems for hospital-based labs and
near-patient testing. Scientists use our discovery systems and sensors for
cutting-edge research to develop a new understanding of health and illness
-- from disease pathology to biomarker identification. We design all of our
systems, sensors, and consumables to deliver better, more-reliable results.
And better results help drive improved health outcomes: earlier,
more-accurate diagnoses; breakthroughs that can lead to novel treatments,
new cures -- innovations to enhance life. A privately held company,
Magellan serves customers through wholly owned subsidiaries: ESA
Biosciences, Dynex Technologies, and TekCel. For more information, visit
http://www.magellanbio.com.
About Ampersand Ventures
Founded in 1988, Ampersand is a leading private equity investment firm
with offices in Wellesley, Massachusetts, and San Diego, California. With
more than $600 million under management, Ampersand pursues a
stage-independent investment strategy across a broad range of industry
sectors, including life sciences and healthcare.
About Abingworth Management
Abingworth is a long-established venture capital firm dedicated to the
life sciences sector on both sides of the Atlantic. The company invests
across all stages of development, including early-stage as well as public
companies. Abingworth has funds under management of over $750 million.
Founded in 1973, Abingworth has offices in London, Cambridge (UK), Menlo
Park (California) and Boston. For more information, visit
http://www.abingworth.com.
About Hambrecht & Quist Capital Management, LLC
A registered investment adviser based in Boston, Massachusetts,
Hambrecht & Quist Capital Management is currently the investment adviser
for two closed-end equity funds, H&Q Healthcare Investors and H&Q Life
Sciences Investors. The Funds invest in small emerging growth equities,
both public and private, in the healthcare and life sciences industries.
For more information, visit http://www.hqcm.com.
About KBL Healthcare Ventures
KBL Healthcare Ventures is a venture capital firm based in New York
City dedicated to investing in private, emerging growth healthcare
companies. KBLs goal is to identify companies that are run by seasoned
management teams and that have the potential to create long-term value in
the healthcare industry. For more information, visit http://www.kblvc.com.
About New England Partners
Founded in 1992, New England Partners is a Boston-based venture capital
firm specializing in making equity investments in technology, healthcare,
and consumer product companies. During the past twenty years, the
professionals at NEP collectively have invested in over 250 companies,
resulting in a successful record of investment realizations through sales,
IPOs and mergers. For more information, visit http://www.nepartners.com.
About Nexus Medical Partners
Nexus Medical Partners is a private equity firm, headquartered in
Boston, MA, specializing in making private equity investments in and
providing strategic assistance to medical technology and selected life
science companies. For more information, visit http://www.nexusmp.com.
About Boston Community Venture Fund
Boston Community Venture Fund (BCVF) is a leading community development
venture capital fund that invests throughout the Northeast in
high-potential businesses that create a "double bottom line" of financial
and social returns. In addition to providing capital, we actively engage
with our portfolio companies to help them achieve their growth objectives.
For more information, visit http://www.bcvfund.com.
Media Contact:
Caroline Grossman - 781.771.5579 - cgrossman@magellanbio.com
s.server=server()
s.channel="News Release"
s.pageName="Magellan Biosciences Closes $50 Million Financing"
s.prop2="109"
s.prop3="11-28-2006"
s.prop4=""
s.prop5=""
/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
var s_code=s.t();if(s_code)document.write(s_code);
| |
|
|
 |
property for sale in balchik varna brovets bansko bulgaria |
|
|
|
|
|
|
|
|
|
Locations
